ALLI ® Orlistat

ALLI ® is a drug based on Orlistat

THERAPEUTIC GROUP: Anti-obesity drugs with peripheral action

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications ALLI ® Orlistat

ALLI® is indicated in the treatment of obesity and overweight when complicated by its risks in conjunction with a balanced and moderately hypocaloric diet.

Mechanism of action ALLI ® Orlistat

The Orlistat contained in ALLI ® is an active ingredient used as a pharmacological support to a balanced diet for weight loss in diseases such as obesity.

The active principle, taken orally and not absorbed by the intestinal mucosa, reaches the gastro-enteric environment, where, given its chemical structure, it is able to interact selectively with the lipases present therein, inhibiting them through a covalent bond.

The inhibition of these enzymes prevents the dietary lipids introduced through the diet from being effectively digested in fatty acids and glycerol, then absorbed through the intestinal mucosa.

The undigested fats, and the active ingredient with its metabolites, will subsequently be excreted through the faeces, significantly varying their consistency and greasiness.

Studies carried out and clinical efficacy

1. ORLISTAT IN OBESE ADOLESCENTS

Study conducted on approximately 500 obese adolescent patients, in which it was shown that the administration of Orlistat could significantly increase the effectiveness of the dietary plan significantly reducing body weight, with a double success rate compared to placebo. The study was conducted for 54 weeks at doses but twice those present in ALLI.

2. ORLISTAT WITHOUT MEDICAL PRESCRIPTION

Work which emphasizes the importance of the possible side effects associated with a wrong intake of Orilstat and the general lack of preparation for the management of drugs such as ALLI. The importance of resorting to medical consultation is therefore reiterated even though this drug can be freely sold without a prescription.

3. ORLISTAT OR DIET?

Interesting study that compared the effects in terms of weight loss, blood pressure improvement and blood chemistry parameters, between Orlistat therapy and a low carbohydrate diet. The data show that dietary treatment can be as effective as pharmacological treatment in ensuring a reduction in body weight and blood chemistry parameters, but more effective in reducing blood pressure.

Method of use and dosage

ALLI ® 60mg hard capsules of Orlistat: the recommended dosage is one 60mg capsule of Orlistat, for a maximum total of 3 daily capsules, to be taken with water, before, during or immediately after meals containing a good lipid quota .

In order for the drug to perform its effect without particularly obvious side reactions, it is important that the amount of food lipids is around 30% of the total caloric quota and that the pharmacological treatment is associated with a general improvement in lifestyle.

ALLI ® Orlistat warnings

Although ALLI ® is sold without a prescription, it is of fundamental importance to consult your doctor before taking it.

Furthermore, in order for the treatment results to be lasting and to improve the health condition of the obese patient, it is necessary, together with the drug therapy, to adopt a balanced and healthy dietary plan and an adequate lifestyle.

During the intake of ALLI ® especially for patients subjected to oral anticoagulant and antidiabetic therapy it is necessary to monitor the hematological picture related to coagulation and glucose metabolism.

Although the specific mechanism of action has not yet been clarified, the intake of Orlistat in patients suffering from hypothyroidism and chronic renal failure, could be accompanied by the simultaneous presence of even relevant side effects.

In addition, to avoid hypovitaminosis related to fat-soluble vitamins, it would be good to design a supplementary protocol with your doctor that includes taking these substances at least two hours after that of ALLI ®

PREGNANCY AND BREASTFEEDING

The absence of studies demonstrating a good safety profile for the health of the fetus, following the intake of Orlistat in pregnancy, does not allow the drug ALLI ® to be used during pregnancy.

At the same time the presence of pharmacokinetic studies that showed the secretion of the active ingredient in breast milk, underline the importance of avoiding the intake of this drug during the lactation period.

Interactions

The interactions described following the intake of ALLI ® are due to the Orlistat's ability to interfere with the normal absorption of active ingredients such as cyclosporine, oral anticoagulants, oral contraceptives, levothyroxine, antiepileptic drugs, fat-soluble vitamins and amiodraone.

It would therefore be advisable to correct the doses, or to administer the drugs far from taking ALLI ®

Contraindications ALLI ® Orlistat

ALLI ® is contraindicated in patients with cholestasis, chronic malabsorption syndrome and hypersensitivity to the active substance or one of its excipients.

Orlistat intake is also contraindicated during breastfeeding and not recommended during pregnancy.

Undesirable effects - Side effects

The various clinical trials carried out and the post-marketing monitoring showed the presence of side effects concentrated above all on the gastro-intestinal level oily losses, flatulence, fatty stools, abdominal pains, faecal incontinence and increased evacuation acts.

Rarely, however, have there been cases of nephropathy, anxiety, headache, coagulation abnormalities and dermatological reactions due to hypersensitivity to the active ingredient.